A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Phase of Trial: Phase III
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 29 Jun 2018 Planned End Date changed from 23 Apr 2019 to 1 Sep 2019.
- 29 Jun 2018 Planned primary completion date changed from 23 Apr 2019 to 1 Sep 2019.
- 15 May 2018 Planned End Date changed from 1 Sep 2019 to 23 Apr 2019.